Page 51 - GPD-3-2

Gene & Protein in Disease β-cell regeneration and stem cell niche

control and weight loss. GPCRs regulate metabolic challenges remain in regulating them at microscopic levels
69
functions such as glucose and energy balance, insulin and maintaining them in culture. Regenerative medicine
production, and glucose homeostasis. Given their role in is revolutionizing disease modeling and drug screening
insulin sensitivity, they are popular therapeutic targets for through kidney cell cultures and organoids. Decellularized
medications targeting T2D. Abdelaziz Ghanemi examines scaffolds infused with iPSC-derived kidney cells hold the
GPCRs and their associated signaling pathways, including potential to create functional replacement organs, enabling
both G protein-dependent and arrestin-dependent organ-on-a-chip technology based on microfluidics
pathways. Arrestin1 and arrestin2 are cytosolic and kidney cell types. Hydrogen materials can regulate
70
73
adaptor proteins with widespread expression, and their stem cell fate, enabling the development of biomimetic
role in T2D treatment is underscored. GPCR adapter tissue structures and therapeutic stem cells. Single-cell
71
proteins, characterized by high structural conservation transcriptomics is expected to advance our knowledge of
and 80% amino acid similarity, can initiate clathrin- cell expansion and design.
coated pits-mediated removal of activated GPCRs from
cell surfaces. In addition, arrestins have been shown to Human PSCs offer an in vitro platform for studying
mediate the G protein-independent signaling pathway cardiovascular disorders. A comprehensive understanding
of GPCRs, demonstrating a pharmacological separation of stem cell biology and their derivatives is essential for
between these two signaling pathways. 68 Nov el medications assessing their advantages and disadvantages. GPCRs
targeting the GLP-1R are currently underway for the are crucial regulators of stem cell maintenance and
treatment of T2D. These medications stimulate insulin development, playing a key role in cardiovascular cell
74
secretion, reduce glucagon secretion, reduce appetite, signaling. Gabor Földes et al. explore the role of GPCRs
and promote early satiety, leading to weight reduction in in the development and functionality of cardiomyocytes,
many patients. Furthermore, researchers have developed endothelial cells, and vascular smooth muscle cells derived
75
drugs that block the enzyme dipeptidyl peptidase IV from PSCs. It suggests that these models could be used
(DPP-IV), thereby raising GLP-1 levels and prolonging to unravel disease mechanisms and formulate treatment
its action. plans. The secretion of hormones from pancreatic islets is
a complex process tightly controlled by GPCRs, suggesting
6. Future prospective and outlook that targeting GPCRs could represent a promising strategy
A computer model has been developed to understand the for regulating islet functionality. Fabian J. Theis et al. draw
intricate interactions between messengers and signaling on RNA-seq datasets from both human and mouse islets to
76
pathways in pancreatic β-cells, incorporating data on support its insights.
glucose metabolism, plasma membrane potential, GPCRs, Future options for diabetes therapy may benefit from
calcium dynamics, and cAMP and phospholipase C targeting cellular signaling networks, as they can promote
pathways that regulate second messenger interactions. the growth of β-cells. These pathways entail interactions
72
This model provides a framework for examining how with the proliferative machinery of β-cells, as well as
changes in metabolism, hormones, and neurotransmitters various ligands and receptors. Uddin et al. comprehensively
affect insulin secretion. The study suggests that the actions assess the potential underlying mechanisms of signaling
of catecholamines, GLP-1, and GIP are significantly pathways, including TLR4, Wnt, JAK-STAT, insulin, and
influenced by the activation of Ca -dependent adenylyl growth factor. The application of cellular signals in
2+
77
cyclases. Furthermore, it reveals that a combination β-cells poses challenges due to differences in expression
of GPCR agonists can enhance insulin secretion more across species, age groups, and tissue types, compounded
effectively than a single pathway, emphasizing the need by a lack of thorough investigation into their specific
to understand connections across second messenger functions. It is important to note that excessive activation
pathways for a better understanding of regulatory sites and of these signaling pathways may negatively impact
pharmaceutical targets in T2D. β-cells. Various therapeutic strategies, including stem cell

Advancements in single-cell multimodal assay differentiation induction and islet transplantation, could
development, computational methodologies, and the be used for diabetes treatment. Identifying molecular
convergence between biology and engineering have targets is crucial for developing novel strategies and
improved our understanding of biological processes improving patient outcomes. The regeneration approach
and algorithm design. Organoid stages enable in vitro seeks to maintain a population of preserved β-cells
organogenesis and clinical diagnostics, paving the way for through in situ exposure to agents that enhance cell
the development of novel treatments. Techniques in genome survival, replication, and insulin secretion. In addition,
editing and genetic circuitry refine organoids, although it entails stimulating the spontaneous conversion of

Volume 3 Issue 2 (2024) 15 doi: 10.36922/gpd.2996